Research Insight
Research Insight
Johnson & Johnson Pharmaceutica NV Idylla Ebola Virus Triage Test Granted Emergency Use Authorizatio
Johnson & Johnson’s commitment to combat Ebola, Janssen Pharmaceutica NV announced that the Idylla™ Ebola Virus Triage Test (Idylla™ EBOV Test) was granted Emergency Use Authorization (EUA) by the U.S. FDA 1. The Idylla™ Ebola Virus Triage Test is a...
Research Insight
Bayer collaborates with US NSAB Project Investigate Additional Adjuvant Therapy in Colon Cancer
Bayer and the U.S. National Surgical Adjuvant Breast and Bowel Project (NSABP), a leading clinical trials cooperative group, are collaborating on a new Phase III study to investigate Stivarga® (regorafenib) as an additional adjuvant therapy in colon cancer.The ARGO...
Research Insight
Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated wi
Following the recommendation of an independent Data Monitoring Committee (DMC), Bayer is terminating its Phase II study investigating riociguat in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) with immediate effect. The DMC is an independent committee...
Research Insight
Edwards Lifesciences’ Philanthropy Impacts 200,000 Underserved Patients Through Every Heartbeat Matt
Edwards Lifesciences Corporation the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that reports from its philanthropic partners in the Every Heartbeat Matters initiative demonstrate they have impacted the global burden of...
Research Insight
Horizon Discovery Introduces High Throughput Platform for Immuno-Oncology Research
Horizon Discovery Group plc, the world leader in the application of gene editing technologies including custom screening and specialized assay services,today announced the launch of a new platform for immuno-oncology research. The platform consists of several high throughput assays...
Research Insight
IMS Health Study: U.S Drug Spending Growth Reaches 8.5 Percent in 2015
According to a new report issued by the IMS Institute for Healthcare Informatics. The surge of new medicines remained strong last year and demand for recently launched brands maintained historically high levels. The savings from branded medicines facing generic...
Research Insight
IMS Health Study: U.S. Drug Spending Growth Reaches 8.5 Percent in 2015
According to a new report issued by the IMS Institute for Healthcare Informatics. The surge of new medicines remained strong last year and demand for recently launched brands maintained historically high levels. The savings from branded medicines facing generic...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
